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Introduction
FTY720 is a recently discovered immunosuppressive
drug that is based on the fungal substance myriocin.
FTY720 is phosphorylated by sphingosine kinase 2
and is in its phosphorylated form a potent agonist for
all known S1P receptors, except S1P2 [1–3]. FTY720
potently inhibits a variety of experimental autoim-
mune disorders and was tested in phase II clinical tri-
als for prevention of renal graft rejection. Currently it
is in a phase III clinical trial for the treatment of mul-
tiple sclerosis [4–6]. The immunosuppressive prop-
erties of FTY720 are mainly based on its ability
toprevent the egress of T cells from secondary
lymphoid organs, sequestering them from the
peripheral blood. Although, the many aspects of the
mechanisms of action of FTY720 are still dis-
cussed, it is now clear that the S1P receptor S1P1
plays a major role in mediating the FTY720 effects
towards lymphocyte migration and trafficking [1,
7–9]. However, since S1P is also an important
chemoattractant in the immune system and modu-
lates T cell responses to chemokines, the immuno-
suppressive properties of FTY720 are likely to be
based on several mechanisms [10].
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Abstract
FTY720 is a novel immunosuppressive drug that inhibits the egress of lymphocytes from secondary lymphoid
tissues and thymus.In its phosphorylated form FTY720 is a potent S1P receptor agonist.Recently it was also
shown that FTY720 can reduce prostaglandin synthesis through the direct inhibition of the cytosolic phos-
pholipase A2 (cPLA2). Since prostaglandins are important mediators of nociception, we studied the effects
of FTY720 in different models of nociception.We found that intraperitoneal administration of FTY720 reduced
dose-dependently the nociceptive behaviour of rats in the formalin assay. Although the antinociceptive doses
of FTY720 were too low to alter the lymphocyte count, prostanoid concentrations in the plasma were dramat-
ically reduced. Surprisingly, intrathecally administered FTY720 reduced the nociceptive behaviour in the for-
malin assay without altering spinal prostaglandin synthesis, indicating that additional antinociceptive mecha-
nisms beside the inhibition of prostaglandin synthesis are involved. Accordingly, FTY720 reduced also the
nociceptive behaviour in the spared nerve injury model for neuropathic pain which does not depend on
prostaglandin synthesis. In this model the antinociceptive effect of FTY720 was similar to gabapentin, a com-
monly used drug to treat neuropathic pain.Taken together we show for the first time that FTY720 possesses
antinociceptive properties and that FTY720 reduces nociceptive behaviour during neuropathic pain.
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Only recently it was demonstrated that FTY720
reduced the release of prostaglandin D2 and cys-
teinyl-leukotrienes from mast cells, independently of
its phosphorylation status and of S1P receptors. In
this cell system FTY720 directly inhibited cPLA2
activity, thus decreasing the release of arachidonic
acid and preventing the subsequent synthesis of
prostaglandins [11]. Therefore it was speculated that
FTY720 may reduce inflammatory responses that
depend on eicosanoid synthesis, such as asthma [11].
However, several reports show that activation of
S1P receptors enhances the spontaneous neuro-
transmitter release at neuromuscular junctions [12]
and facilitates neuronal growth factor (NGF)-induced
increases in the excitability of sensory neurons from
dorsal root ganglia (DRG) [13, 14]. More recently, it
was shown that S1P facilitates also glutamate secre-
tion in hippocampal neurons [15].Thus, since the acti-
vation of S1P receptors enhances the glutamate
release in several neuronal systems, FTY720 may pro-
mote nociceptive processing not only by enhancing
glutamate release of the sensory DRG neurons but as
well by facilitating glutamate secretion of excitatory glu-
tamatergic neurons within the spinal cord.On the other
hand FTY720 may decrease nociception by reducing
prostaglandin synthesis through inhibition of cPLA2.
Here we investigated whether FTY720 influences
nociception in animal models that depend on the
synthesis of prostaglandins and in animal models
that do not depend on prostaglandin synthesis.
Therefore we investigated which net effect FTY720
has on nociceptive processing. We found that sys-
temic as well as intrathecally (i.th.) administered
FTY720 decreased nociceptive behaviour in adult
rats in the formalin assay. Additionally, FTY720
decreased the nociceptive behaviour in the spinal
nerve injury (SNI) model for neuropathic pain similar
to gabapentin, a commonly described drug for the
treatment of neuropathic pain that appears to modu-
late nociceptive processing by binding to the 2-
subunit of voltage-gated calcium channels [16].
Materials and methods
Animals
Sprague Dawley rats (250–300 g) were supplied by
Charles River Wiga GmbH (Sulzfeld, Germany). The ani-
mals had free access to food and water and were main-
tained in climate- (24±0.5°C) and light-controlled rooms. In
all experiments the ethics guidelines for investigations in
conscious animals were obeyed and the procedures were
approved by the local Ethics Committee.
Implantation of lumbar catheters 
Implantation of lumbar catheters was performed as
described previously [17] with the exception that polyethyl-
ene catheters (ID 0.28 mm, OD 0.61 mm, Neolab,
Heidelberg, Germany) were used.
Behavioural assays 
The observer was unaware of the treatments in all tests.
The formalin assay [17], hot-plate test [18] and the assess-
ment of motor co-ordination using the pole test [19] were
performed as described previously.
Neuropathic pain 
Rats were anaesthetized with ketamine and midazolam
(0.5–1 mg/kg i.p.) and the sciatic nerve (N.ischiadicus)
with its three branches was exposed by blunt dissection.
The common pereonal and the tibial branches were tight-
ly ligated with 5-0 silk thread and cut distally from the lig-
ature [20]. For the sham-operated animals the same pro-
cedure was applied but the nerve was not ligated and cut.
Behavioural testing started before surgery and two base-
line values for each group were recorded on separate
days. Two time points (day 3 and 7) were recorded after
surgery to confirm the neuropathic pain state. Animals
were placed on an elevated wire grid and the lateral side
of the plantar surface of the paw was stimulated using a
Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio
VA, Italy). For cold plate testing the rats were placed on a
cold steel plate (1±0.5°C) and the total number of flinches
were counted in 5 min intervals. Von Frey hair testing 
[20] and the aceton test were performed as described 
previously [21].
Leukocyte count 
Animals were anaesthetized with isoflurane (2%) and
200 µl of blood were collected by punction of the v.jugularis
and unlabelled blood cells were counted using a Cell Dyne
cytometer (Abbott Diagnostics, Wiesbaden, Germany)
according to the manufacturer’s instruction.
© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing LtdJ. Cell. Mol. Med.Vol 12, No 3, 2008
997
LC-MS/MS analysis 
The following eicosanoids and their stable metabolites
were monitored by LC-MS/MS: PGF2, PGE2, PGD2,
TxB2, 11-dh-TxB2, 6-keto-PGF1,  
12-PGJ2, 15d-PGJ2,
13, 14-dh-15-keto-PGD2, 13,14-dh-15-keto-PGE2, PGA2,
PGB2, 15d-PGD2 and LTB4.Lumbal spinal cords were pre-
pared and directly frozen with liquid nitrogen. Then 200 µl
PBS was added and the tissue quickly homogenized with
a potter. 100 µl of the homogenate were mixed with 50 µl
water, 20 µl methanol and 20 µl internal standard solution 




10 ng/ml of [
2H4]-PGF2 and [
2H4]-6-keto-PGF1 in
methanol) and extracted twice with 800 µl ethyl acetate.
The organic phase was removed at a temperature of 45°C
under a gentle stream of nitrogen. The residues were
reconstituted with 50 µl of acetonitrile/water/formic acid
(20:80:0.0025, v/v, pH 4.0), and injected into the LC-
MS/MS system.
Instrumentation
Sample analysis was performed by using liquid chro-
matography-electrospray ionization-tandem mass spec-
trometry (LC-ESI-MS/MS). The LC-MS/MS system con-
sisted of an API 4000 triple-mass spectrometer (Applied
Biosystems, Darmstadt, Germany) equipped with a Turbo-
V-source operating in negative ESI mode, an Agilent 1100
binary HPLC pump and degasser (Agilent, Böblingen,
Germany) and an HTC Pal autosampler (Chromtech,
Idstein) fitted with a 100 µl LEAP syringe (Axel Semrau
GmbH, Sprockhövel, Germany). A cooling stack was used
to store the samples at 4°C in the autosampler. An inlet
valve was used to truncate non-relevant signals (10-port,
VICI Valco Instruments, Houston, USA). High-purity nitro-
gen for the mass spectrometer was produced by a NGM
22-LC/MS nitrogen generator (CMC Instruments,
Eschborn, Germany).
LC-MS/MS conditions 
For the chromatographic separation a Synergi Hydro-RP
column and pre-column were used (150 x 2 mm I.D., 4-µm
particle size and 80 Å pore size from Phenomenex,
Aschaffenburg, Germany). A linear gradient was employed
at a flow rate of 300 µl/min.Mobile phase A was water/formic
acid (100:0.0025, v/v, pH 4.0) and mobile phase B was ace-
tonitrile/formic acid (100:0.0025, v/v). Sample solvent was
acetonitrile/water/formic acid (20:80:0.0025, v/v, pH 4.0).
Total run time was 16 min and injection volume of samples
was 45 µl. Retention times of the eicosanoids which were
detectable in the spinal cord extracts were 6-keto-PGF1,
TxB2, PGF2, PGE2 and PGD2 were 7.4 min, 8.0 min, 
8.2 min, 8.7 min and 9.2 min, respectively.
The mass spectrometer was operated in the negative
ion mode with an electrospray voltage of (3300 V at 450°C.
Multiple reaction monitoring (MRM) was used for quantifi-
cation. The mass transitions used were m/z 351.1 → → m/z
271.2 for PGE2, m/z 351.1 → → m/z 233.0 for PGD2, m/z
353.1 → → m/z 193.0 for PGF2, m/z 369.1 → → m/z 162.9 for
6-keto-PGF1, m/z 369.1 → → m/z 168.9 for TxB2, m/z 355.1
→ → m/z 275.1 for [
2H4]-PGE2, m/z 355.1 → → m/z 237.0 for
[
2H4]-PGD2, m/z 357.0 → → m/z 197.1 for [
2H4]-PGF2, m/z
373.2 → → m/z 167.1 for [
2H4]-6-keto-PGF1 and m/z 373.2
→ → m/z 173.0 for [
2H4]-TxB2 all with a dwell time of 50 ms.
All quadrupoles were working at unit resolution.
Quantitation was performed with Analyst Software V1.4
(Applied Biosystems, Darmstadt, Germany) using the inter-
nal standard method (isotope-dilution mass spectrometry).
Ratios of analyte peak area and internal standard peak area
(y-axis) were plotted against concentration (x-axis) and cal-
ibration curves for each prostaglandin were calculated by
least square regression with 1/concentration
2 weighting.
Values that were under the detection limit were set as 0.
FTY720 and FTY720-phosphate 
(FTY-P) analysis 
After liquid–liquid extraction concentrations of FTY720 and
FTY720-P and the internal standards C17-sphingosine
(C17-SPH) and C17-sphingosine-1-phosphate (C17-S1P)
were determined by liquid chromatography coupled to
mass spectrometry. HPLC analysis was done under gradi-
ent conditions using a Luna C18 column (150 cm L x 2 mm
ID, 5 µm particle size and 100 Å pore size, Phenomenex,
Aschaffenburg, Germany). MS/MS analyses were per-
formed on a 4000 Q TRAP triple quadrupole mass spec-
trometer with a Turbo V source (Applied Biosystems,
Darmstadt, Germany). Precursor-to-product ion transitions
of m/z 308 → 255 for FTY720, m/z 388 → 290 for FTY720-
P, m/z 286 → 238 for C17-SPH and 366 → 250 for C17-S1P
were used for the MRM. Concentrations of the calibration
standards, quality controls and unknowns were evaluated
by Analyst software (version 1.4; Applied Biosystems,
Darmstadt, Germany). Variations in accuracy and intraday
and interday precision (n = 6 for each concentration,
respectively) were <15% over the range of calibration.
Concentrations under the detection level were set as 0.
Results
To study the effects of FTY720 on nociceptive behav-
iour we first employed the formalin assay since this
assay depends strongly on prostaglandin synthesis
and especially on the spinal PGE2 synthesis [17, 22].
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Intraperitoneally (i.p.) injected FTY720 significantly
reduced, at rather low doses (0.001 and 0.01 mg/kg),
the nociceptive behaviour of adult rats (Fig. 1A).
Surprisingly the antinociceptive effect disappeared
when the doses were further increased (0.1–
1 mg/kg; Fig. 1A). The FTY720 dose with the great-
est antinociceptive potency (0.01 mg/kg) did not alter
motor abilities of treated rats as determined by the
pole assay (Fig. 1B) or the basal pain threshold as
determined by the hot plate assay (Fig. 1C). Notably,
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Fig. 1 FTY720 decreases the nociceptive behaviour of rats in the formalin assay. (A) Increasing concentrations of
FTY720 or saline were given i.p. 15 min prior to the formalin injection in one hind paw. The number of flinches from
0–15 (phase I) min, 16–60 min (phase II) are shown.The data are expressed as the mean ± S.E.M. of six animals per
group. Two-tailed Student’s t-test: *P0.025, **P0.01, ***P0.001 as compared to animals receiving only vehicle.
(B, C) The effect of 0.01 mg/kg FTY720 i.p. on motor co-ordination was assessed using the pole test (B) and on pain
thresholds using the hot-plate test (C). Data are presented as mean ± S.E.M. of 5–6 animals. (D) The number of white
blood cells (WBC) and lymphocytes (LYM) were determined before (baseline, BL) and after a single i.p. administration
of FTY720 to the indicated times. Data are presented as mean ± S.E.M. of 4–5 animals. Two-tailed Student’s t-test:
*P0.02 as compared to baseline. (E) Eicosanoid concentrations in the plasma 1 hr after i.p. injection of 0.01 mg/kg
FTY720. Data are presented as mean ± S.E.M. (n = 8–9). Two-tailed Student’s t-test: *P0.03 as compared to rats
that received only vehicle.J. Cell. Mol. Med.Vol 12, No 3, 2008
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doses from 0.1–10 mg/kg were previously reported
to induce the immunosuppressive actions of FTY720
in rats [9]. Accordingly, at the highest dose (1 mg/kg)
a significant reduction in the lymphocyte count
occurred (Fig. 1D). At the dose with the strongest
antinociceptive effect (0.01 mg/kg) a tendency
towards a decreased lymphocyte count was seen,
but did not reach statistical significance (Fig. 1D).
This gives a first indication that the immunosuppres-
sive properties of FTY720 may not play a major role
in mediating its antinociceptive effects. In contrast,
1 hr after i.p. administration of 0.01 mg/kg FTY720,
the plasma concentrations of PGE2, PGD2, PGF2
and thromboxane A2 (TxA2), as determined by 
its stable metabolite TxB2, were dramatically
decreased. Interestingly, not all eicosanoid concen-
trations were altered by FTY720, since the plasma
concentrations of PGI2, as determined by its stable
metabolite 6-ketoPGF1, were unchanged. The dra-
matic decrease of the eicosanoid level in the plasma,
and here especially the decreased PGE2 concentra-
tions, could serve to explain the antinociceptive effect
of FTY720, since inhibition of PGE2 synthesis gener-
ally reduces the nociceptive behaviour in the forma-
lin assay [17, 22, 23].
To investigate whether the antinociceptive effect of
FTY720 has also a central component we adminis-
tered FTY720 i.th. Rats that received FTY720 i.th.
exhibited a significant decrease in their nociceptive
behaviour in the formalin assay as compared to rats
that received only saline (Fig. 2A). Neither FTY720
nor its phosphorylated form was detected in the plas-
ma after i.th. administration (Fig. 2B) and according-
ly, even with the highest dose of FTY720 (80 µM,
© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 FTY720 (i.th.) decreases the nociceptive behaviour in the formalin assay without altering the prostanoid synthe-
sis. (A) FTY720 (3 µM) or saline were given i.th. 15 min prior to the formalin injection in one hind paw. The data are
expressed as the mean ± S.E.M. of 7–10 animals per group. Two-tailed Student’s t-test: *P0.035 as compared to
control animals. (B) FTY720 and FTY720-phosphate concentrations were determined in the plasma of animals 1 hr
after administering either 0.01 mg/kg i.p. or 3 µM i.th. FTY720. Data are expressed as the mean ± S.E.M. of 4–5 ani-
mals per group (nd = not detectable). (C) The number of white blood cells (WBC) were determined before and 1 hr
after a single i.th. administration of 3 µM FTY720. Data are presented as mean ± S.E.M. of 4–5 animals. (D)
Eicosanoids were extracted 1 hr after formalin injection from spinal cord segments L4–L5. Where indicated FTY720 
(3 µM) was given i.th.. Data are presented as mean ± S.E.M. (n = 7–10).1000
i.th.) no effect on the number of white blood cells was
observed (Fig. 2C). Since i.p. administration of
FTY720 decreases the prostaglandin concentrations
in the plasma, we compared the prostanoid synthe-
sis in the spinal cord of animals that received
FTY720 i.th.with control animals 1 hr after the forma-
lin injection. Out of 14 eicosanoids that were moni-
tored only five eicosanoids were above the detection
limit in the spinal cord extracts and for none of these
five eicosanoids significant differences between both
animal groups were observed (Fig. 2D). This sug-
gests that the antinociceptive effects of FTY720 in
the spinal cord are not based on cPLA2 inhibition.
Since the immunosuppressive effects of FTY720 are
mediated by S1P1 [24] we tested which role this recep-
tor plays in mediating the spinal antinociceptive effects
of FTY720. Interestingly, neither i.th. or i.p. administra-
tion of SEW2871, a selective S1P1agonist, caused sig-
nificant effects on the nociceptive behaviour of rats in
the formalin assay (Fig. 3A and B). In accordance with
the above described findings with FTY720, i.th. admin-
isteredSEW2871didnotalterthewhitebloodcellcount
even at the highest dose of (80 µM) (Fig. 3C), while as
expected i.p. administered SEW2871 significantly
decreased the white blood cell count in the peripheral
blood. These findings support the notion that the
immunosuppressive property of FTY720 seems not to
play a major role in mediating its antinociceptive effect.
Moreover, i.p.administered SEW2871 increased signif-
icantly the plasma concentrations of PGE2 as well as
PGF2 (Fig.3D).Owing to the fact that increased PGE2
levelsareconnectedwithincreasednociception[17,22,
23], this finding further speaks against a role of S1P1 in
mediating the antinociceptive effects of FTY720.
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Fig.3 SEW2871 does not alter nociceptive behaviour in the formalin assay. (A) Increasing concentrations of SEW2871
or saline were given i.th.15 min prior to the formalin injection in one hind paw.The number of flinches from 0–15 (phase
I) min, 16–60 min (phase II) are shown. The data are expressed as the mean ± S.E.M. of six animals per group. (B)
Same as panel A except that SEW2871 (4 mg/kg, i.p.) or saline were given 15 min prior to the formalin injection in one
hind paw. The data are expressed as the mean ± S.E.M. of six animals per group (n.s.; not significant). (C) The num-
ber of white blood cells (WBC) were determined before and 1 hr after a single administration of 10µl SEW2871 (80 µM)
i.th. or 4 mg/kg SEW2871 i.p.. Data are presented as mean + S.E.M. of at least seven animals.Two-tailed Student’s t-
test: *P0.003 as compared to controls. (D) Eicosanoids were determined in the plasma in untreated animals and 1
hr after formalin injection. Where indicated SEW2871 (4 mg/kg) was given i.p.. Data are presented as mean ± S.E.M.
(n = 7–9).Two-tailed Student’s t-test: *P0.003 as compared to animals treated only with formalin.J. Cell. Mol. Med.Vol 12, No 3, 2008
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Fig. 4 FTY720 decreases nociceptive behaviour in the SNI model for neuropathic pain. The nociceptive behaviour in
the SNI model for neuropathic pain was determined ipsilateral (full symbols) and contralateral (empty symbols) before
the operation (BL) and at the indicated times after the operation.The animals received gabapentin (red), FTY720 (blue,
dotted line) or vehicle (black). Sham operated animals are shown in grey. FTY720 (1x daily, 0.01 mg/kg i.p.) and
gabapentin (2x daily 25 mg/kg) were given starting at day 7 after the operation. The mechanical threshold was deter-
mined using a plantar aesthesiometer (A) or von Frey hairs (B).Thermal allodynia was determined using the cold plate
test (C) or the acetone test (D).Data are presented as mean + S.E.M.of six animals per group.(E) FTY720 was applied
to adult rats for 14 days (1x daily, 0.01 mg/kg i.p.) and the number of white blood cells (WBC) and lymphocytes (LYM)
was determined at the indicated times. After day 14 administration of FTY720 was discontinued. Data are presented
as mean + S.E.M. of five animals.Two-tailed Student’s t-test: *P0.5, **P0.01, ***P0.001 as compared to animals
not receiving FTY720 or gabapentin.1002
Next, we tested the antinociceptive actions of
FTY720 in the spared nerve injury (SNI) model for
neuropathic pain, a pain model that has a different
pathophysiological mechanism as compared to the
formalin assay and is known to be independent of
prostaglandin synthesis [19, 20]. Mechanical and
thermal allodynia were allowed to develop over 7
days after surgery before the animals received
intraperitoneally FTY720, gabapentin (positive con-
trol) or phosphate-buffered saline over 2 weeks.
Mechanical allodynia as determined by a plantar
aesthesiometer (Fig. 4A) and von Frey hair testing
(Fig. 4B) as well as thermal allodynia as determined
by cold plate (Fig. 4C) and acetone test (Fig. 4D),
were significantly decreased after the treatment with
FTY720. Interestingly, the antinociceptive effect of
FTY720 was similar to that of gabapentin, a com-
monly prescribed drug for the treatment of neuro-
pathic pain (Fig.4A–D) [25].The chronic daily admin-
istration of the low doses of FTY720 caused a statis-
tically significant decrease in the number of peripher-
al blood lymphocytes (Fig. 4E). However, the number
of lymphocytes was still within the range that is found
in normal, healthy rats [26].
Discussion
Since it has been described that FTY720 can direct-
ly inhibit cPLA2 [11], which plays a major role in noci-
ceptive processing, we speculated that FTY720 may
reduce nociception in prostaglandin-dependent ani-
mal models for inflammatory pain. We present here
data which show that FTY720 indeed decreases the
nociceptive behaviour in the formalin assay, an ani-
mal model for acute pain that depends on
prostaglandin synthesis [17, 22].However, the under-
lying mechanism(s) that allow FTY720 to exhibit its
antinociceptive property remain unclear.
According to the previous report showing direct
inhibition of cPLA2 by FTY720, i.p. administered
FTY720 decreased the plasma concentrations of
PGE2, PGD2, PGF2 and TxB2. The decreased
eicosanoid concentrations could serve to explain the
antinociceptive effects of FTY720 in the formalin
assay. However, i.th. administered FTY720 reduced
significantly the nociceptive behaviour in the formalin
assay without causing any significant changes in the
spinal eicosanoid synthesis. Moreover, FTY720
decreased very effectively the nociceptive behaviour
in the SNI model for neuropathic pain, although this
model does not depend on prostaglandin synthesis
[19, 20].Taken together these findings make it seem
unlikely that the inhibition of cPLA2 is the sole reason
for the observed antinociceptive effects. However, it
is also obvious that the observed effect of FTY720 on
the peripheral prostaglandin synthesis will signifi-
cantly add to the antinociceptive effect of FTY720
due to the role of prostaglandins in nociceptor sensi-
tization.
Owing to the fact that the antinociceptive active
dose of FTY720 (0.01 mg/kg) did not induce a sig-
nificant decrease in the number of lymphocytes in
the peripheral blood and since intrathecal adminis-
tration of FTY720 had an antinociceptive effect
without altering the lymphocyte count, it is also
doubtful that the immunosuppressive properties of
FTY720 are the main cause for its antinociceptive
effect. However, since the repeated daily adminis-
tration of FTY720 decreases the lymphocyte count
in the peripheral blood by about 50% during the
treatment in the SNI model, it is possible that the
inflammatory component in this model is reduced
and therefore might add to the antinociceptive effect
of FTY720.
Since S1P1 mediates the immunosuppressive
properties of FTY720, we employed the S1P1 ago-
nist SEW2871, to investigate more closely the role of
lymphocyte depletion for the antinociceptive activity
of FTY720. I.p. administered SEW2871 decreased
the white blood cell number in the peripheral blood
and raised at the same time the plasma concentra-
tions of PGE2, PGD2, PGF2 and TxB2 which would
suggest a pronociceptive effect of S1P1 activation.
The increased prostaglandin levels are in accor-
dance with previous reports which describe that S1P
treatment as well as S1P1 activation upregulate
cyclooxygenase-2 and prostaglandin synthesis in
several cell types [27–29]. Since SEW2871 treat-
ment did not enhance the nociceptive behaviour in
the formalin assay, either the increased plasma con-
centrations of the prostaglandins are insufficient to
influence nociception in the formalin assay or
SEW2871 exerts an unknown antinociceptive effect
which compensates the pronociceptive effect of the
raised prostaglandin levels. However, taken together
the data show that S1P1 activation alone is not to
sufficient to execute an antinociceptive effect.
Though we cannot rule out that at least in the SNI
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model for neuropathic pain the S1P1-mediated
immunosuppressive actions of FTY720 might partic-
ipate in the antinociceptive effects.
Another mechanism for the antinociceptive prop-
erties of FTY720 could be based on the activation of
S1P receptors in the central nervous system or in the
periphery. It is currently discussed that its immuno-
suppressive actions might be based on FTY720 act-
ing as a ‘functional S1P1 receptor antagonist’, induc-
ing internalization and degradation of the receptor in
lymphocytes to block S1P-directed migration out of
lymphnodes [7, 24, 30, 31]. Thus, the reduced
antinociceptive effect at higher doses in the formalin
assay and in the SNI model may similarly be based
on the downregulation of S1P receptors on cells that
participate in nociceptive processing.
Neuropathic pain states often occur after peripher-
al or central nerve damage due to injuries, metabol-
ic damages, viral infections or tumour growth. The
pharmacological therapy of most neuropathic pain
forms is to date unsatisfactory, since the available
drugs are either not very effective or are limited in
their usefulness by unwanted side effects [32, 33].
Since the reported side effects for FTY720 are rela-
tive moderate [5, 34, 35] and the most effective
antinociceptive doses are lower than the doses used
for immunosuppression, our data suggest that S1P-
receptor agonists, such as FTY720, may turn out to
be useful analgesic drugs for the treatment of neuro-
pathic pain. If S1P1 does not mediate the central
antinociceptive effect of FTY720 and since FTY720
is not an agonist for S1P2, then S1P3, S1P4 or S1P5
are the most likely candidates to mediate the central
antinociceptive effect. As so far no selective agonists
or antagonists for these three receptors are avail-
able, our hypothesis that these receptors are of
importance for the antinociceptive mode of action of
FTY720 remains speculative. Thus, the future devel-
opment of selective agonists for S1P receptors
S1P3–5 could open the perspective to circumvent the
immunosuppression, the main side effect of FTY720,
while keeping the analgesic potency.
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